StockData
Abbott Laboratories logo

Abbott Laboratories (ABT) stock

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3049% above fair value
$108.52+1.27 (+1.18%)

Close on Nov 13, 2026Market cap $187.78BP/E 40.2Yield 2.21%

Abbott Laboratories cash

Cash and short-term investments held at the end of each period.

Abbott Laboratories's cash was $4.30B at Sep 30, 2026. For fiscal 2025 it was $8.94B, up 12.2% from the year before. Over ten years it grew 3.9% a year on average. The highest annual figure on record is $18.78B in fiscal 2016.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$8.94B+12.2%
FY2024Dec 31, 2024$7.97B+9.5%
FY2023Dec 31, 2023$7.28B-28.4%
FY2022Dec 31, 2022$10.17B-0.8%
FY2021Dec 31, 2021$10.25B+43.4%
FY2020Dec 31, 2020$7.15B+72.7%
FY2019Dec 31, 2019$4.14B+1.3%
FY2018Dec 31, 2018$4.09B-57.5%
FY2017Dec 31, 2017$9.61B-48.8%
FY2016Dec 31, 2016$18.78B+206.5%
FY2015Dec 31, 2015$6.13B+37.3%
FY2014Dec 31, 2014$4.46B-44.9%
FY2013Dec 31, 2013$8.10B-46.6%
FY2012Dec 31, 2012$15.17B+87.4%
FY2011Dec 31, 2011$8.10B+6.2%
FY2010Dec 31, 2010$7.63B-31.1%
FY2009Dec 31, 2009$11.07B+79.8%
FY2008Dec 31, 2008$6.15B+118.1%
FY2007Dec 31, 2007$2.82B+441.2%
FY2006Dec 31, 2006$521.19M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$4.30B-44.4%
Q2 FY2026Jun 30, 2026$5.60B-23.1%
Q1 FY2026Mar 31, 2026$7.30B+6.6%
Q4 FY2025Dec 31, 2025$8.94B+12.2%
Q3 FY2025Sep 30, 2025$7.73B-0.7%
Q2 FY2025Jun 30, 2025$7.28B+0.9%
Q1 FY2025Mar 31, 2025$6.84B+2.9%
Q4 FY2024Dec 31, 2024$7.97B+9.5%
Q3 FY2024Sep 30, 2024$7.79B+10.5%
Q2 FY2024Jun 30, 2024$7.22B-11.5%
Q1 FY2024Mar 31, 2024$6.65B-30.2%
Q4 FY2023Dec 31, 2023$7.28B-28.4%
Q3 FY2023Sep 30, 2023$7.05B-28.9%
Q2 FY2023Jun 30, 2023$8.16B-12.2%
Q1 FY2023Mar 31, 2023$9.53B+16.8%
Q4 FY2022Dec 31, 2022$10.17B-0.8%
Q3 FY2022Sep 30, 2022$9.91B+2.2%
Q2 FY2022Jun 30, 2022$9.29B+3.9%
Q1 FY2022Mar 31, 2022$8.16B-2.6%
Q4 FY2021Dec 31, 2021$10.25B+43.4%
Q3 FY2021Sep 30, 2021$9.69B+104.9%
Q2 FY2021Jun 30, 2021$8.94B+77.6%
Q1 FY2021Mar 31, 2021$8.37B+128.2%
Q4 FY2020Dec 31, 2020$7.15B+72.7%
Q3 FY2020Sep 30, 2020$4.73B+9.1%
Q2 FY2020Jun 30, 2020$5.04B+49.2%
Q1 FY2020Mar 31, 2020$3.67B+12.5%
Q4 FY2019Dec 31, 2019$4.14B+1.3%
Q3 FY2019Sep 30, 2019$4.34B-42.6%
Q2 FY2019Jun 30, 2019$3.38B+3.4%
Q1 FY2019Mar 31, 2019$3.26B-19.3%
Q4 FY2018Dec 31, 2018$4.09B-57.5%
Q3 FY2018Sep 30, 2018$7.55B-32.6%
Q2 FY2018Jun 30, 2018$3.26B-66.8%
Q1 FY2018Mar 31, 2018$4.04B-54.4%
Q4 FY2017Dec 31, 2017$9.61B-48.8%
Q3 FY2017Sep 30, 2017$11.20B–
Q2 FY2017Jun 30, 2017$9.84B–
Q1 FY2017Mar 31, 2017$8.86B–
Q4 FY2016Dec 31, 2016$18.78B–

More Abbott Laboratories figures

See a number that looks wrong?